A carregar...
Inhibition of Rac1 reverses enzalutamide resistance in castration-resistant prostate cancer
Enzalutamide, an androgen receptor inhibitor, has been clinically approved for the treatment of metastatic castration-resistant prostate cancer (CRPC) in the United States. However, patients only benefit from enzalutamide for a short period of time as resistance may develop. Therefore, it is vital t...
Na minha lista:
| Publicado no: | Oncol Lett |
|---|---|
| Main Authors: | , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
D.A. Spandidos
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7400968/ https://ncbi.nlm.nih.gov/pubmed/32782617 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2020.11823 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|